Clinical Trial Update: Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of denosumab in patients with recurrent or unresectable giant cell tumor of bone has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: GCT, Giant Cell Tumor of Bone | Phase 2 | Status: COMPLETED | Results posted: 2014-03-05